| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jeremy Burrows | Q87131067 |
| Timothy N C Wells | Q55182082 | ||
| P2093 | author name string | Paul Willis | |
| David Waterson | |||
| Didier Leroy | |||
| Thomas Spangenberg | |||
| Brice Campo | |||
| Emilie Burlot | |||
| Sarah Jeanneret | |||
| Stephanie Cherbuin | |||
| P2860 | cites work | Evidence of Artemisinin-Resistant Malaria in Western Cambodia | Q22061854 |
| Identification of an antimalarial synthetic trioxolane drug development candidate | Q22061876 | ||
| Thousands of chemical starting points for antimalarial lead identification | Q24289329 | ||
| Challenges in antimalarial drug discovery | Q37924296 | ||
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. | Q39616001 | ||
| Plasmodium berghei parasite transformed with green fluorescent protein for screening blood schizontocidal agents | Q41914401 | ||
| Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum | Q41940698 | ||
| Optimal dose finding for novel antimalarial combination therapy | Q42210267 | ||
| The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies | Q42562371 | ||
| Targeting the parasite in the mosquito: rationale and practicality. | Q47165551 | ||
| Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study | Q24598695 | ||
| Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 | ||
| Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes | Q24651549 | ||
| Global phenotypic screening for antimalarials | Q26824875 | ||
| Designing the next generation of medicines for malaria control and eradication | Q26859195 | ||
| Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential | Q27670499 | ||
| Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target | Q27674154 | ||
| Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery | Q27861956 | ||
| A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes | Q28472751 | ||
| A research agenda for malaria eradication: drugs | Q28476806 | ||
| Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery | Q28477602 | ||
| The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites | Q28480979 | ||
| P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action | Q28481199 | ||
| The open access malaria box: a drug discovery catalyst for neglected diseases | Q28533977 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| Chemical genetics of Plasmodium falciparum | Q29617272 | ||
| Vivax malaria: neglected and not benign | Q29619167 | ||
| A Research Agenda to Underpin Malaria Eradication | Q33818020 | ||
| Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs | Q33898575 | ||
| Can primaquine therapy for vivax malaria be improved? | Q33965030 | ||
| Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening | Q34122581 | ||
| Imidazolopiperazines: lead optimization of the second-generation antimalarial agents | Q34270117 | ||
| Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria | Q34693880 | ||
| Costs and cost-effectiveness of malaria control interventions--a systematic review | Q35589032 | ||
| Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen | Q35598598 | ||
| Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast | Q36095096 | ||
| The global pipeline of new medicines for the control and elimination of malaria | Q36320249 | ||
| A framework for assessing the risk of resistance for anti-malarials in development | Q36340996 | ||
| First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials | Q36573154 | ||
| In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen | Q36736936 | ||
| Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy | Q37076814 | ||
| Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice | Q37352712 | ||
| Malaria, sexual development and transmission: retrospect and prospect | Q37574197 | ||
| Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination | Q37687630 | ||
| The state of the art in anti-malarial drug discovery and development | Q37852739 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| eukaryote | Q19088 | ||
| Plasmodium falciparum | Q311383 | ||
| antimalarial | Q521616 | ||
| drug discovery | Q1418791 | ||
| biomedical investigative technique | Q66648976 | ||
| organism form | Q55597235 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 128-139 | |
| P577 | publication date | 2013-07-17 | |
| 2014-01-01 | |||
| P1433 | published in | Parasitology | Q15753259 |
| P1476 | title | Antimalarial drug discovery - the path towards eradication | |
| P478 | volume | 141 |
| Q36137064 | A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments |
| Q27644391 | A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria |
| Q34597517 | A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs |
| Q27728080 | A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria |
| Q37613101 | Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites |
| Q36951722 | Current therapies and future possibilities for drug development against liver-stage malaria |
| Q64067595 | Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone |
| Q41915664 | Cyclopalladated organosilane-tethered thiosemicarbazones: novel strategies for improving antiplasmodial activity |
| Q46124569 | Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity |
| Q35868585 | Discovery of Dual-Stage Malaria Inhibitors with New Targets |
| Q36591461 | Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase |
| Q33599811 | Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers |
| Q47872179 | Effect of ozonide OZ418 against Schistosoma japonicum harbored in mice |
| Q38878704 | Effect of piplartine and cinnamides on Leishmania amazonensis, Plasmodium falciparum and on peritoneal cells of Swiss mice |
| Q38894544 | Emerging paradigms in anti-infective drug design |
| Q33636531 | Evaluation of aminohydantoins as a novel class of antimalarial agents. |
| Q40501587 | Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy |
| Q38399949 | Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance |
| Q38923200 | Improved antiparasitic activity by incorporation of organosilane entities into half-sandwich ruthenium(II) and rhodium(III) thiosemicarbazone complexes |
| Q47096821 | Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission |
| Q37093155 | New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections |
| Q38770142 | Novel drug discovery for Chagas disease |
| Q91665347 | One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites |
| Q36215894 | Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission |
| Q38866063 | Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity |
| Q33891625 | Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum |
| Q35662591 | Strand-specific RNA sequencing in Plasmodium falciparum malaria identifies developmentally regulated long non-coding RNA and circular RNA. |
| Q36947737 | Substrate and Inhibitor Specificity of the Plasmodium berghei Equilibrative Nucleoside Transporter Type 1 |
| Q56380008 | Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of Dihydroorotate Dehydrogenase |
| Q36996257 | Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity |
| Q35592537 | The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions |
| Q26766144 | The biology of Theileria parva and control of East Coast fever - Current status and future trends |
| Q35311620 | Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate |
| Q36179646 | Validation of a chloroquine-induced cell death mechanism for clinical use against malaria |
| Q41588963 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria |
| Q30836732 | Working towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study |
Search more.